PERTH, Australia – Biotron Ltd. is crunching the data from a recently concluded phase II trial in HIV-1 that tested its lead compound BIT-225 in combination with antiretroviral (ARV) drugs, and the Melbourne-based company said it believes its approach to tackling viruses like HIV could wipe out the virus completely, Biotron CEO Michelle Miller told BioWorld Asia.